| CHILDREN'S HOSPITAL MEDICAL CENTER Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122967 | COMPOSITIONS AND PRODUCTS CONTAINING R-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering R-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The R-equol enantiomer can be produced by chiral-phase column separation from a racemic mixture of equol. | 05-17-2012 |
| 20120020878 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS - The present invention comprises a method for delivering pharmaceutical and/or imaging agents within and/or through the dermal, mucosal and other cellular membranes, and across the blood-brain barrier, utilizing a fusogenic protein. The fusogenic protein is associated with a phospholipid membrane, such as a liposome. The liposome may include dioleoylphosphatidylserine, a negatively charged long-chain lipid. Alternatively, the liposome is comprised of a mixture of negatively charged long-chain lipids, neutral long-chain lipids, and neutral short-chain lipids. Preferred fusogenic proteins include saposin C and other proteins, polypeptides and peptide analogs derived from saposin C. The active agent contained within the liposome may comprise biomolecules and/or organic molecules. This technology can be used for both cosmetic and medicinal applications in which the objective is delivery of the active agent within and/or beneath biological membranes or across the blood-brain barrier and neuronal membranes. | 01-26-2012 |
| 20120010234 | USE OF VEGF-D IN THE DIAGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) DISEASE - Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided. | 01-12-2012 |
| 20120004427 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES - A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained. | 01-05-2012 |
| 20120004189 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 01-05-2012 |
| 20110312918 | METHOD FOR IDENTIFYING AGENTS FOR INHIBITING CELL MOTILITY AND INVASIVENESS - The present invention provides a novel mechanistic pathway and methods related to this pathway for the identification of compounds for the treatment of diseases involving cell proliferation, invasion and/or metastasis such as cancer. In particular, the instant invention relates to the phosphatase activity of Eya and the Eya-Six complex as a target for identifying novel therapeutic agents for the treatment of proliferative, invasive and/or metastatic disorders, and compositions identified using the methods disclosed herein. | 12-22-2011 |
| 20110301046 | Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis - The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products. | 12-08-2011 |
| 20110217715 | GENE EXPRESSION IN DUCHENNE MUSCULAR DYSTROPHY - Gene expression in peripheral blood from individuals with Duchenne muscular dystrophy (DMD), compared to control individuals, demonstrated differential gene sets that could be used in a method to diagnose DMD, to evaluate effect of DMD therapy, and/or to evaluate propensity to DMD. | 09-08-2011 |
| 20110212898 | CHIMERIC PEPTIDES FOR THE REGULATION OF GTPASES - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 09-01-2011 |
| 20110207659 | OLIGOSACCHARIDE COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF INFECTION - Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described. | 08-25-2011 |
| 20110200580 | METHODS OF TREATMENT AND PREVENTION OF DIET-INDUCED OBESITY AND SEQUELAE THEREOF - Disclosed are methods of treating or preventing diet-induced obesity and/or one or more sequelae thereof in a subject. These methods comprise administering to a subject in need of treatment or at risk for developing diet-induced obesity and/or one or more sequelae thereof, a therapeutically effective amount of a pharmaceutical composition comprising at least one inhibitor of RP 105 and/or MD-I activity. Also disclosed are methods of identifying compounds that inhibit development of diet-induced obesity and/or one or more sequelae thereof. In some aspects, these methods comprise: providing at least one first cell comprising TLR4, MD-2. RP105. MD-K and a TLR4-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with lipopolysaccharide and with a candidate compound; and determining a level of expression of the reporter in the presence of the LPS and the candidate compound, in some aspects, these methods comprise: providing at least one first cell comprising TLR2, TLR1, TLR6, MD-2, RP H/S, MD-K and a TLR2-responsive promoter operably linked to a nucleic acid sequence encoding a reporter, contacting the at least one first cell with a lipopeptide ligand of TLR2 and with a candidate compound, and determining a level of expression of the reporter in the presence of the lipopeptide ligand of TLR2 and the candidate compound | 08-18-2011 |
| 20110195500 | METHODS AND COMPOSITIONS FOR MITIGATING EOSINOPHILIC ESOPHAGITIS BY MODULATING LEVELS AND ACTIVITY OF EOTAXIN-3 - Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed. | 08-11-2011 |
| 20110177996 | REGULATORY PROTEINS IN LUNG REPAIR AND TREATMENT OF LUNG DISEASE - The DNA-binding protein Sox17 has been found to play an important role in repair of pulmonary tissue after damage, disease, or injury. Nucleic acids encoding proteins involved in pulmonary repair, such as Sox17 and Spdef, can be used as a therapeutic composition for treating pulmonary disease. Methods of treatment of pulmonary injuries or pulmonary diseases are also disclosed, as are methods of identifying compounds effective in treating pulmonary injuries and diseases. | 07-21-2011 |
| 20110136153 | Use of VEGF-D in the Diagnosis of Lymphangioleiomyomatosis (LAM) Disease - Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided. | 06-09-2011 |
| 20110135651 | METHOD AND COMPOSITION FOR ENHANCING HEMATOPOIETIC STEM CELL MOBILIZATION - A therapeutic combination for improved mobilization of the hematopoietic stem and progenitor cells, and methods of use thereof are described. The therapeutic combination comprises G-CSF and an inhibitor of the EGFR signaling pathway. The role of EGFR is established by several lines of evidence, including use of quantitative trait locus analysis to map the chromosomal location of the non-G-CSF enhancement of hematopoietic stem and progenitor cells mobilization. Further, several different modes of inhibiting EGFR signaling all provide for an enhanced G-CSF induced mobilization of hematopoietic stem cells. | 06-09-2011 |
| 20110020274 | MOBILIZATION OF HEMATOPOIETIC STEM CELLS - Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject. | 01-27-2011 |
| 20110003844 | REGULATION OF CARDIAC CONTRACTILITY AND HEART FAILURE PROPENSITY - The methods and compositions of the present invention find use in altering expression of PKCα in transgenic animals. The compositions of the invention include isolated transgenic animal cells, transgenic tissue, transgenic animals, and transgenic mice. The transgenic animals of the invention exhibit altered PKCα activity. The methods allow generation of transgenic animals with altered expression of PKCα. The invention allows modulation of cardiac contractility. In particular, the invention provides a method for altering the susceptibility of a transgenic animal to cardiomyopathy. A transgenic animal of the invention finds use in identifying anti-cardiomyopathic compounds. | 01-06-2011 |
| 20100286053 | PLASMINOGEN ACTIVATOR INHIBITOR AMELIORATION OF NEWBORN HYPOXIC ISCHEMIC BRAIN INJURY - Plasminogen activators as potential therapeutic targets in neonatal hypoxia ischemia (HI) brain injury. Use of plasminogen activator inhibitor-1 (PAI-1) to ameliorate HI encephalopathy related disease. Use of PAI-1 as preventive treatment of cerebral palsy (CP). | 11-11-2010 |
| 20100267575 | GENE ARRAY TECHNIQUE FOR PREDICTING RESPONSE IN INFLAMMATORY BOWEL DISEASES - Disclosed are methods for classifying individuals having or suspected of having an inflammatory bowel disease, such as Crohn's Disease or Ulcerative Colitis, as “responders” or “non-responders” to first-line treatment, generally comprising the steps of a) obtaining, a biological sample from the individual, b) isolating mRNA from the biological sample c) determining a gene expression profile from the biological sample; and d) comparing the gene expression profile of the individual to a reference gene expression profile or other suitable control such that changes in expression can be used to stratify individuals and predict efficacy of first-line therapy. A gene expression system is further provided for carrying out these methods. | 10-21-2010 |
| 20100261774 | Methods for the modulation of Leishmania major infection in mammals - Embodiments of the invention include methods for treating an infection of a mammal by an organism, such as | 10-14-2010 |
| 20100172897 | Diagnosis and Prevention of Fetal Heart Disease - The present invention relates to a method for assessing the likelihood of the presence or formation of fetal heart disease (such as HLHS) in a fetus. In this methodology, the mother, either before or during pregnancy, is tested for the presence of anti-strep antibodies. If positive, the fetus is evaluated and monitored for the presence of fetal heart disease; the fetus can be treated, if appropriate. In addition, either prior to pregnancy or during the first trimester, the mother can be treated to prevent the formation of such antibodies or to neutralize their presence or effect fetal heart tissue. | 07-08-2010 |
| 20100120705 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 05-13-2010 |
| 20100038317 | HEMOFILTRATION SYSTEM AND METHOD BASED ON MONITORED PATIENT PARAMETERS, SUPERVISORY CONTROL OF HEMOFILTRATION, AND ADAPTIVE CONTROL OF PUMPS FOR HEMOFILTRATION - A multipurpose hemofiltration system and method are disclosed for the removal of fluid and/or soluble waste from the blood of a patient. The system continuously monitors the flow rates of drained fluid, blood, and infusate. When necessary, the pumping rates of the infusate, drained fluid and blood are adjusted to remove a preselected amount of fluid from the blood in a preselected time period. A supervisory controller can monitor patient parameters, such as heart rate and blood pressure, and adjust the pumping rates accordingly. The supervisory controller uses fuzzy logic to make expert decisions, based upon a set of supervisory rules, to control each pumping rate to achieve a desired flow rate and to respond to fault conditions. An adaptive controller corrects temporal variations in the flow rate based upon an adaptive law and a control law. | 02-18-2010 |
| 20090311663 | Organ Transplant Solutions and Method for Transplanting Organs - A preservation solution for organs waiting to be transplanted is disclosed; the method of using the solution in a transplantation procedure is also disclosed. The preservation solutions comprise a balanced isotonic aqueous solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount, together with an effective amount of a mutein of the C5 | 12-17-2009 |
| 20090297496 | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases - The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome, | 12-03-2009 |
| 20090269373 | Saposin C-DOPS: A Novel Anti-Tumor Agent - Compositions and methods for treating subjects with disorders characterized by hyper-proliferating cells such as tumors and cancers are provided. The compositions comprise agents that are combinations of saposin C (or prosaposin-related polypeptides) and phospholips (or inner leaflet components). This anti-tumor agent is administered in the methods of the invention according to a dosing regimen. Administering an agent of the invention results in a positive therapeutic response in a subject with a tumor. | 10-29-2009 |
| 20090233275 | EOTAXIN-3 IN EOSINOPHILIC ESOPHAGITIS - Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed. | 09-17-2009 |
| 20090203617 | CHIMERIC PEPTIDES FOR THE REGULATION OF GTPASES - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 08-13-2009 |
| 20090018185 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 01-15-2009 |
| 20080242615 | SURFACTANT PROTEIN-D FOR PREVENTION AND TREATMENT OF LUNG INFECTIONS AND SEPSIS - Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Administration of SP-D protein or fragments thereof is useful for the prevention or treatment of sepsis or lung infection. | 10-02-2008 |
